Cubist Pharmaceuticals LLC clinical trials

Acquired by Merck & Co., Inc, Jan 21, 2015 · source ↗

The registry lists 65 studies whose lead sponsor is Cubist Pharmaceuticals LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 22, 2022.

• 65studies on the registry
• 0open to participants now

Studies

Recruiting first, then most recently updated. Showing 50 of 65. List all 65 → · All Merck & Co., Inc studies →

• A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)CompletedNCT01598311Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)TerminatedNCT00638157Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)CompletedNCT02070757Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard AntibioticsCompletedNCT00136292Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial PneumoniaCompletedNCT00538694Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. PneumoniaeCompletedNCT00540072Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive InfectionsCompletedNCT00679835Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic AntibioticsCompletedNCT01019395Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)CompletedNCT02266706Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)CompletedNCT02387372Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)CompletedNCT02276482Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)CompletedNCT01597505Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)CompletedNCT02019420Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/ReplacementTerminatedNCT00448864Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)CompletedNCT02341599Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion SettingTerminatedNCT01175707Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA BacteremiaTerminatedNCT00695903Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated PneumoniaTerminatedNCT01853982Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal InfectionsCompletedNCT01445678Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01696643Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901341Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedNCT01275755Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901302Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedNCT01901328Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including PyelonephritisCompletedNCT01345929Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal InfectionsCompletedNCT01147640Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract InfectionsCompletedNCT00921024Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedNCT01207427Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of CB-183,315 in Participants With Clostridium Difficile InfectionCompletedNCT01085591Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal ImpairmentTerminatedNCT01104662Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSACompletedNCT01419184Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure InfectionsCompletedNCT00711802Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)CompletedNCT01728376Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)CompletedNCT01922011Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study to Evaluate Daptomycin Given During Dialysis and After DialysisCompletedNCT00882557Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by StaphylococciCompletedNCT00428844Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)CompletedNCT00490737Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or ErysipelasCompletedNCT00295178Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Cubicin(R) for Complicated Post-surgical Wound InfectionsTerminatedNCT00651131Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00241722Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain MedicationCompletedNCT00101998Phase 2

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative IleusCompletedNCT00388258Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Daptomycin for the Treatment of Infections Due to Gram-Positive BacteriaTerminatedNCT00055198Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. AureusCompletedNCT00093067Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy SubjectsCompletedNCT02508753Phase 1

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure InfectionsTerminatedNCT00102947Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative IleusCompletedNCT00205842Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical CystectomyCompletedNCT00708201Phase 4

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00259922Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc

• Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer PainCompletedNCT00256932Phase 3

  Sponsor listed in the registry: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc